Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 39 clinical trials
Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

rate in patients with inactive CHB. The purpose of this study is to establish a national multi-center, prospective real world study to compare the efficacy of different antiviral treatment

  • 0 views
  • 16 Jan, 2022
  • 1 location
Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B

Multicenter, Open-label, Randomized Controlled Trial Chronic hepatitis B male and female adults on antiviral treatment for hepatitis B, without cirrhosis who are currently HBV DNA (-) and HBeAg

  • 0 views
  • 25 Sep, 2021
  • 10 locations
Effectiveness of Antiviral Treatment in Cirrhotic Patients With Low-level Hepatitis B Virus DNA Levels

Multicenter, Open-label, Randomized Controlled Trial Male and female adults with liver cirrhosis due to chronic hepatitis B virus infection who have low-level viremia and are beyond treatment indications by current guidelines. To assess the efficacy of Tenofovir Alafenamide (TAF) in reducing liver-related events (hepatocellular carcinoma, liver-related events and death, decompensated …

  • 0 views
  • 04 Jan, 2022
  • 6 locations
IFN Beta-1b and Ribavirin for Covid-19

As of 1 July 2020, more than 10 million people been confirmed to have infected by SARS-CoV-2, resulting in more than 500,000 deaths. No specific antiviral treatment for the SARS-CoV-2 is

SARS
critical illness
antiviral drugs
interferon
  • 0 views
  • 24 Jan, 2021
  • 1 location
Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19

influenza that early treatment with antimicrobials is associated with better outcome. The hypothesis is that this holds for COVID-19 and that early antiviral treatment may prevent progression to the later

  • 0 views
  • 28 Oct, 2021
  • 1 location
Tenofovir Alafenamide(TAF) Reduces the Risk of Hepatocellular Carcinoma(HCC) Recurrence

loads (<2000 IU/ml) is still unclear. In EASL 2017 guideline, all patients with compensated or decompensated cirrhosis need antiviral treatment, with any detectable HBV DNA level and

  • 0 views
  • 19 Jul, 2021
  • 4 locations
Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks

Influenza outbreaks are a prevalent event in nursing homes (NHs). We will study baloxavir compared to oseltamivir when used for influenza prophylaxis when facilities identify an index incident case of influenza. This study will help guide nursing home's decision making and demonstrate the effectiveness of a novel antiviral for preventing …

oseltamivir
  • 0 views
  • 28 Aug, 2021
  • 1 location
Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines

Treatment with Tenofovir Alafenamide(TAF) in Chronic Hepatitis B (CHB) patients classified as beyond treatment indication of current international guidelines (e.g. aged more than 40 years old and 4 log HBV-DNA IU/mL < 8) is expected to bring improvement in long-term clinical outcomes. This expected result may expand the treatment indications …

tenofovir
estimated creatinine clearance
ml 7
hepatitis b antigen
cirrhosis
  • 0 views
  • 29 Dec, 2021
  • 1 location
Zoster Eye Disease Study

This is a multi-center, randomized, double-masked, placebo-controlled clinical trial of suppressive valacyclovir for one year in immunocompetent study participants with an episode of dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, and/or iritis due to Herpes Zoster Ophthalmicus (HZO) in the year prior to enrollment.

rash
vaccination
antiviral drugs
zoster vaccine
valacyclovir
  • 780 views
  • 06 May, 2021
  • 85 locations
Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study

This is a phase three study to evaluate the safety and efficacy of Pradefovir treatment in chronic hepatitis B patients. Subject will be randomized to Pradefovir group and TDF group at a ratio of 2:1. Treatment duration will be 96w in randomization and followed by 48w in open. The interim …

fumarate
hepatitis
tenofovir
  • 10 views
  • 25 Jan, 2021
  • 1 location